Listen and follow our podcasts on:

Viatris.

In this second podcast episode of a 4-part series, haematologists continue to explore different clinical scenarios and challenges in managing thrombosis.

In this conversation, they discuss how to treat thrombosis in patients with cancer, covering:

 

  • When and how to use heparins and/or direct oral anticoagulants (DOACs)

  • The benefits of primary thromboprophylaxis and its efficacy in various tumour types

  • How the patient's involvement could result in an improved quality of life

 

E-learning

After listening to the podcast series, take the e-learning assessment to test your knowledge and earn CME credits.

 

Clinical takeaways

 

  • Heparins and/or DOACs are safe and efficient in treating thrombosis in cancer patients

  • Primary thromboprophylaxis is efficient in selected cancer patients but still remains a matter of debate for the majority of tumours

  • To improve quality of life, it is important to involve the patient in the treatment decision-making process

Prof. Dimitrios A. Tsakiris, MD was born in Thessaloniki, Greece and obtained his Diploma of Medicine (1982) at the Medical School, Aristotle University of Thessaloniki, Greece. He started his training in Clinical Haematology at the AHEPA University Hospital in Thessaloniki and completed it at the University Hospital Basel in Basel, Switzerland, where he has been working since 1987. He holds a license for Clinical Haematology and Laboratory Haematology. He spent one year (1996) as a Research Associate in Platelet Research at the Mount Sinai School of Medicine, New York, NY, USA. He has held a professorship in Haematology at the Faculty of Medicine, University of Basel, Switzerland since 2004 and serves also as a visiting Professor of Hematology at the Medical School of the Aristotle University of Thessaloniki. He has served as Head of Haemostasis since 2009 and Head of Diagnostic Haematology and Haemostasis (2014-2021), as well as member of the Stem Cell Transplant and Cell-Therapy Center Basel at the University Hospital Basel, Switzerland. Since 2021 he has been Director of Thrombosis and Haemostasis and Co-Head Hematology at SYNLAB Suisse SA, Switzerland. His main fields of scientific interests are platelet activation, platelet disorders, diagnosis and treatment of bleeding disorders and thrombophilia, disorders of haemostasis and endothelial cells after stem cell transplants. He has presented over 140 peer-reviewed original articles and reviews.

Dr Lars Asmis is Director at the Centre for Perioperative Thrombosis and Haemostasis in Zurich, Switzerland.  He completed his medical training at the University of Bern and has subsequently held positions at Inselspital Bern, University of Geneva and USZ Zurich.  In 2002 he worked as a visiting scientist at Johns Hopkins University in Baltimore, USA.  Dr Asmis has held a number of leadership positions including Co-president of the Swiss Working Party for Hemostasis from 2020 to 2021.  He has authored more than 50 peer-reviewed publications.

Dr Lars Asmis has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Viatris

Listen and follow our podcasts on:

Viatris.

In this second podcast episode of a 4-part series, haematologists continue to explore different clinical scenarios and challenges in managing thrombosis.

In this conversation, they discuss how to treat thrombosis in patients with cancer, covering:

 

  • When and how to use heparins and/or direct oral anticoagulants (DOACs)

  • The benefits of primary thromboprophylaxis and its efficacy in various tumour types

  • How the patient's involvement could result in an improved quality of life

 

E-learning

After listening to the podcast series, take the e-learning assessment to test your knowledge and earn CME credits.

 

Clinical takeaways

 

  • Heparins and/or DOACs are safe and efficient in treating thrombosis in cancer patients

  • Primary thromboprophylaxis is efficient in selected cancer patients but still remains a matter of debate for the majority of tumours

  • To improve quality of life, it is important to involve the patient in the treatment decision-making process

Prof. Dimitrios A. Tsakiris, MD was born in Thessaloniki, Greece and obtained his Diploma of Medicine (1982) at the Medical School, Aristotle University of Thessaloniki, Greece. He started his training in Clinical Haematology at the AHEPA University Hospital in Thessaloniki and completed it at the University Hospital Basel in Basel, Switzerland, where he has been working since 1987. He holds a license for Clinical Haematology and Laboratory Haematology. He spent one year (1996) as a Research Associate in Platelet Research at the Mount Sinai School of Medicine, New York, NY, USA. He has held a professorship in Haematology at the Faculty of Medicine, University of Basel, Switzerland since 2004 and serves also as a visiting Professor of Hematology at the Medical School of the Aristotle University of Thessaloniki. He has served as Head of Haemostasis since 2009 and Head of Diagnostic Haematology and Haemostasis (2014-2021), as well as member of the Stem Cell Transplant and Cell-Therapy Center Basel at the University Hospital Basel, Switzerland. Since 2021 he has been Director of Thrombosis and Haemostasis and Co-Head Hematology at SYNLAB Suisse SA, Switzerland. His main fields of scientific interests are platelet activation, platelet disorders, diagnosis and treatment of bleeding disorders and thrombophilia, disorders of haemostasis and endothelial cells after stem cell transplants. He has presented over 140 peer-reviewed original articles and reviews.

Dr Lars Asmis is Director at the Centre for Perioperative Thrombosis and Haemostasis in Zurich, Switzerland.  He completed his medical training at the University of Bern and has subsequently held positions at Inselspital Bern, University of Geneva and USZ Zurich.  In 2002 he worked as a visiting scientist at Johns Hopkins University in Baltimore, USA.  Dr Asmis has held a number of leadership positions including Co-president of the Swiss Working Party for Hemostasis from 2020 to 2021.  He has authored more than 50 peer-reviewed publications.

Dr Lars Asmis has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Viatris

Listen and follow our podcasts on:

Viatris.

In this second podcast episode of a 4-part series, haematologists continue to explore different clinical scenarios and challenges in managing thrombosis.

In this conversation, they discuss how to treat thrombosis in patients with cancer, covering:

 

  • When and how to use heparins and/or direct oral anticoagulants (DOACs)

  • The benefits of primary thromboprophylaxis and its efficacy in various tumour types

  • How the patient's involvement could result in an improved quality of life

 

E-learning

After listening to the podcast series, take the e-learning assessment to test your knowledge and earn CME credits.

 

Clinical takeaways

 

  • Heparins and/or DOACs are safe and efficient in treating thrombosis in cancer patients

  • Primary thromboprophylaxis is efficient in selected cancer patients but still remains a matter of debate for the majority of tumours

  • To improve quality of life, it is important to involve the patient in the treatment decision-making process

Prof. Dimitrios A. Tsakiris, MD was born in Thessaloniki, Greece and obtained his Diploma of Medicine (1982) at the Medical School, Aristotle University of Thessaloniki, Greece. He started his training in Clinical Haematology at the AHEPA University Hospital in Thessaloniki and completed it at the University Hospital Basel in Basel, Switzerland, where he has been working since 1987. He holds a license for Clinical Haematology and Laboratory Haematology. He spent one year (1996) as a Research Associate in Platelet Research at the Mount Sinai School of Medicine, New York, NY, USA. He has held a professorship in Haematology at the Faculty of Medicine, University of Basel, Switzerland since 2004 and serves also as a visiting Professor of Hematology at the Medical School of the Aristotle University of Thessaloniki. He has served as Head of Haemostasis since 2009 and Head of Diagnostic Haematology and Haemostasis (2014-2021), as well as member of the Stem Cell Transplant and Cell-Therapy Center Basel at the University Hospital Basel, Switzerland. Since 2021 he has been Director of Thrombosis and Haemostasis and Co-Head Hematology at SYNLAB Suisse SA, Switzerland. His main fields of scientific interests are platelet activation, platelet disorders, diagnosis and treatment of bleeding disorders and thrombophilia, disorders of haemostasis and endothelial cells after stem cell transplants. He has presented over 140 peer-reviewed original articles and reviews.

Dr Lars Asmis is Director at the Centre for Perioperative Thrombosis and Haemostasis in Zurich, Switzerland.  He completed his medical training at the University of Bern and has subsequently held positions at Inselspital Bern, University of Geneva and USZ Zurich.  In 2002 he worked as a visiting scientist at Johns Hopkins University in Baltimore, USA.  Dr Asmis has held a number of leadership positions including Co-president of the Swiss Working Party for Hemostasis from 2020 to 2021.  He has authored more than 50 peer-reviewed publications.

Dr Lars Asmis has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Viatris

Listen and follow our podcasts on:

Viatris.

In this second podcast episode of a 4-part series, haematologists continue to explore different clinical scenarios and challenges in managing thrombosis.

In this conversation, they discuss how to treat thrombosis in patients with cancer, covering:

 

  • When and how to use heparins and/or direct oral anticoagulants (DOACs)

  • The benefits of primary thromboprophylaxis and its efficacy in various tumour types

  • How the patient's involvement could result in an improved quality of life

 

E-learning

After listening to the podcast series, take the e-learning assessment to test your knowledge and earn CME credits.

 

Clinical takeaways

 

  • Heparins and/or DOACs are safe and efficient in treating thrombosis in cancer patients

  • Primary thromboprophylaxis is efficient in selected cancer patients but still remains a matter of debate for the majority of tumours

  • To improve quality of life, it is important to involve the patient in the treatment decision-making process

Prof. Dimitrios A. Tsakiris, MD was born in Thessaloniki, Greece and obtained his Diploma of Medicine (1982) at the Medical School, Aristotle University of Thessaloniki, Greece. He started his training in Clinical Haematology at the AHEPA University Hospital in Thessaloniki and completed it at the University Hospital Basel in Basel, Switzerland, where he has been working since 1987. He holds a license for Clinical Haematology and Laboratory Haematology. He spent one year (1996) as a Research Associate in Platelet Research at the Mount Sinai School of Medicine, New York, NY, USA. He has held a professorship in Haematology at the Faculty of Medicine, University of Basel, Switzerland since 2004 and serves also as a visiting Professor of Hematology at the Medical School of the Aristotle University of Thessaloniki. He has served as Head of Haemostasis since 2009 and Head of Diagnostic Haematology and Haemostasis (2014-2021), as well as member of the Stem Cell Transplant and Cell-Therapy Center Basel at the University Hospital Basel, Switzerland. Since 2021 he has been Director of Thrombosis and Haemostasis and Co-Head Hematology at SYNLAB Suisse SA, Switzerland. His main fields of scientific interests are platelet activation, platelet disorders, diagnosis and treatment of bleeding disorders and thrombophilia, disorders of haemostasis and endothelial cells after stem cell transplants. He has presented over 140 peer-reviewed original articles and reviews.

Dr Lars Asmis is Director at the Centre for Perioperative Thrombosis and Haemostasis in Zurich, Switzerland.  He completed his medical training at the University of Bern and has subsequently held positions at Inselspital Bern, University of Geneva and USZ Zurich.  In 2002 he worked as a visiting scientist at Johns Hopkins University in Baltimore, USA.  Dr Asmis has held a number of leadership positions including Co-president of the Swiss Working Party for Hemostasis from 2020 to 2021.  He has authored more than 50 peer-reviewed publications.

Dr Lars Asmis has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Viatris

Programme summary
Listen to the podcast now
Other episodes of this series
Monitoring Anticoagulation: Yes or No?

Monitoring Anticoagulation: Yes or No?

A clinical discussion on anticoagulation monitoring

Cancer and Thrombosis

Cancer and Thrombosis

A podcast discussion on treating thrombosis in patients with cancer

Current Episode
VTE: What is the optimal duration of antithrombotic treatment?

VTE: What is the optimal duration of antithrombotic treatment?

Part 3 of a 4-part series on thrombosis

Perioperative thromboprophylaxis revisited

Perioperative thromboprophylaxis revisited

Minimising the risk of thrombosis in surgical patients

Share this programme
This educational programme is supported by an Independent Educational Grant from Viatris.
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Viatris.
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
HEMOSTASIS CONNECT

HEMOSTASIS CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Pfizer, Takeda, Viatris and Pentapharm.

Meet the experts Independent IME approved
Programme summary
  • clock Duration MIN
  • clock Language(s) flag
Listen to the podcast now
Other episodes of this series
Monitoring Anticoagulation: Yes or No?

Monitoring Anticoagulation: Yes or No?

A clinical discussion on anticoagulation monitoring

Cancer and Thrombosis

Cancer and Thrombosis

A podcast discussion on treating thrombosis in patients with cancer

Current Episode
VTE: What is the optimal duration of antithrombotic treatment?

VTE: What is the optimal duration of antithrombotic treatment?

Part 3 of a 4-part series on thrombosis

Perioperative thromboprophylaxis revisited

Perioperative thromboprophylaxis revisited

Minimising the risk of thrombosis in surgical patients

Share this programme
This educational programme is supported by an Independent Educational Grant from Viatris.
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Viatris.
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
HEMOSTASIS CONNECT

HEMOSTASIS CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Pfizer, Takeda, Viatris and Pentapharm.

Meet the experts Independent IME approved
Programme summary
  • clock Duration MIN
  • clock Language(s) flag
Listen to the podcast now
Other episodes of this series
Monitoring Anticoagulation: Yes or No?

Monitoring Anticoagulation: Yes or No?

A clinical discussion on anticoagulation monitoring

Cancer and Thrombosis

Cancer and Thrombosis

A podcast discussion on treating thrombosis in patients with cancer

Current Episode
VTE: What is the optimal duration of antithrombotic treatment?

VTE: What is the optimal duration of antithrombotic treatment?

Part 3 of a 4-part series on thrombosis

Perioperative thromboprophylaxis revisited

Perioperative thromboprophylaxis revisited

Minimising the risk of thrombosis in surgical patients

Share this programme
This educational programme is supported by an Independent Educational Grant from Viatris.
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Viatris.
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
HEMOSTASIS CONNECT

HEMOSTASIS CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Pfizer, Takeda, Viatris and Pentapharm.

Meet the experts Independent IME approved
Programme summary
  • clock Duration MIN
  • clock Language(s) flag
Listen to the podcast now
Other episodes of this series
Monitoring Anticoagulation: Yes or No?

Monitoring Anticoagulation: Yes or No?

A clinical discussion on anticoagulation monitoring

Cancer and Thrombosis

Cancer and Thrombosis

A podcast discussion on treating thrombosis in patients with cancer

Current Episode
VTE: What is the optimal duration of antithrombotic treatment?

VTE: What is the optimal duration of antithrombotic treatment?

Part 3 of a 4-part series on thrombosis

Perioperative thromboprophylaxis revisited

Perioperative thromboprophylaxis revisited

Minimising the risk of thrombosis in surgical patients

Share this programme
This educational programme is supported by an Independent Educational Grant from Viatris.
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Viatris.
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
HEMOSTASIS CONNECT

HEMOSTASIS CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Pfizer, Takeda, Viatris and Pentapharm.

Meet the experts Independent IME approved

Other programmes of interest

video Video
Oncology 
ADCs in HR+/HER2- metastatic breast cancer

Optimising treatment strategies and AE management

Experts
Dr Barbara Pistilli
Endorsed by
GRASP
ICAN international cancer advocacy network Biomarker Collaborative Exon20group
  • download Downloadable
    Resources
  • clock MIN
  • calendar May 2025

Educational programme supported by an Independent Educational Grant from AstraZeneca.
podcast Podcast

Episode

2

of 2

episode
Oncology 
The HER2 diagnostic and treatment landscape in NSCLC: Episode 2

Navigating common treatment scenarios in HER2-mutant non-small cell lung cancer

Experts
Dr Eric Singhi, Dr Isabel Preeshagul, Oncology Brothers (Moderators)
Endorsed by
ICAN international cancer advocacy network Biomarker Collaborative Exon20group
  • download Downloadable
    Resources
  • clock 18 MIN
  • calendar Apr 2025

Educational programme supported by an Independent Educational Grant from Bayer.
publication Publication
Oncology 
Emerging molecular testing paradigms in NSCLC management

Experts
Prof. Frédérique Penault-Llorca, Prof. Mark Socinski
  • download Downloadable
    Resources
  • clock 20 MIN
  • calendar Apr 2025

Educational programme supported by an Independent Educational Grant from Bayer.
animated-video Animated Video
Oncology 
Elacestrant in ER+/HER2- metastatic breast cancer with ESR1-mut tumors

An overview of the EMERALD subgroup analyses

Experts
Prof. Javier Cortés
  • download Downloadable
    Resources
  • clock 8 MIN
  • calendar Apr 2025

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only.
podcast Podcast

Episode

1

of 2

episode
Oncology 
The HER2 diagnostic and treatment landscape in NSCLC: Episode 1

A medical oncologist and a pathologist share their perspectives on best practices in identifying HER2-directed NSCLC

Experts
Prof. Fernando López-Ríos, MD, PhD, Dr Devika Das, Oncology Brothers (Moderators)
Endorsed by
ICAN international cancer advocacy network Biomarker Collaborative Exon20group
  • download Downloadable
    Resources
  • clock 20 MIN
  • calendar Apr 2025

Educational programme supported by an Independent Educational Grant from Bayer.
publication Publication
Oncology 
Survey on the evolving role of the oncology nurse in the USA

Survey findings presented at ONS 2025 and published in the journal Healthcare

Experts
Nina Grenon, Natasha Pinheiro, Karen Waldrop, Brittni Prosdocimo
  • download Downloadable
    Resources
  • clock 7 MIN
  • calendar Apr 2025

Educational programme supported by an Independent Educational Grant from Bayer.